Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Index
-
Market Cap
1.11B
Enterprise Value
2.50B
Income
-80.73M
Sales
559.42M
Book/sh
-0.85
Cash/sh
0.19
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
1460
IPO
Nov 09, 2020
P/E
-
Forward P/E
14.08
PEG
-
P/S
1.98
P/B
-
P/C
17.38
P/FCF
-
EV/EBITDA
21.85
EV/Sales
4.47
Quick Ratio
0.88
Current Ratio
1.76
Debt/Eq
-
LT Debt/Eq
-
Option/Short
No / Yes
EPS (ttm)
-0.26
EPS next Y
0.23
EPS next Q
-0.04
EPS this Y
163.55%
EPS next Y
266.57%
EPS next 5Y
-
EPS past 3/5Y
- -
Sales past 3/5Y
91.85% -
EPS Y/Y TTM
-178.26%
Sales Y/Y TTM
-4.47%
EPS Q/Q
-99.15%
Sales Q/Q
-20.26%
Insider Own
69.48%
Insider Trans
0.00%
Inst Own
5.17%
Inst Trans
-0.70%
ROA
-6.05%
ROE
-
ROIC
-7.21%
Gross Margin
61.35%
Oper. Margin
13.35%
Profit Margin
-14.43%
SMA20
-11.47%
SMA50
-7.96%
SMA200
-32.26%
Trades
Shs Outstand
330.28M
Shs Float
103.22M
52W High
9.94 -67.00%
52W Low
2.94 11.56%
Volatility
5.29% 6.07%
ATR (14)
0.22
RSI (14)
38.71
Beta
0.20
Rel Volume
0.58
Avg Volume
688.05K
Volume
397,680
Perf Week
-9.14%
Perf Month
-21.15%
Perf Quarter
-8.89%
Perf Half Y
-29.61%
Perf YTD
-36.06%
Perf Year
-62.43%
Perf 3Y
-61.37%
Perf 5Y
-66.70%
Perf 10Y
-
Prev Close
3.32
Price
3.28
Change
-1.20%
Date Action Analyst Rating Change Price Target Change
Dec-09-25Initiated Barclays Underweight $5
Nov-04-25Downgrade Deutsche Bank Buy → Hold $8
Oct-14-25Upgrade Morgan Stanley Equal-Weight → Overweight $14
Sep-23-25Upgrade Deutsche Bank Hold → Buy $14
Feb-14-25Initiated UBS Buy $18
Jan-29-24Upgrade Barclays Equal Weight → Overweight $10 → $17
Oct-20-23Upgrade Citigroup Sell → Neutral $5 → $10
Sep-21-23Initiated Barclays Equal Weight $10
Sep-07-22Initiated Morgan Stanley Equal-Weight $10
Sep-06-22Downgrade Citigroup Buy → Sell $12 → $5
Jul-03-26 04:01PM
Jul-01-26 04:00AM
Jun-22-26 06:48PM
Jun-18-26 05:51AM
04:00AM
11:59PM Loading…
Jun-15-26 11:59PM
04:01PM
Jun-10-26 04:30PM
Jun-08-26 06:41AM
04:00AM
Jun-04-26 04:00AM
Jun-03-26 04:30PM
Jun-02-26 04:30PM
Jun-01-26 04:30AM
May-11-26 04:30AM
04:30PM Loading…
May-06-26 04:30PM
09:27AM
Apr-30-26 04:30PM
Apr-24-26 08:30AM
Mar-30-26 07:58PM
07:55PM
Mar-18-26 06:15PM
09:18AM
Mar-17-26 09:18AM
Mar-04-26 03:00AM
Feb-26-26 04:00PM
Feb-15-26 04:08AM
Feb-11-26 11:00AM
Feb-05-26 03:00AM
Feb-04-26 01:39PM
03:00AM Loading…
Feb-02-26 03:00AM
Jan-29-26 03:00AM
Jan-22-26 09:26AM
Jan-16-26 08:52AM
Jan-09-26 03:16AM
Jan-07-26 05:00PM
Jan-06-26 03:00PM
07:15AM
Dec-31-25 04:30PM
Dec-29-25 02:40PM
Dec-22-25 03:26PM
02:00AM
Dec-21-25 09:03AM
Dec-19-25 03:30AM
Dec-17-25 02:30AM
Dec-16-25 11:48AM
Dec-11-25 09:30AM
Dec-05-25 05:06AM
Dec-04-25 01:39PM
Dec-02-25 08:10PM
Nov-28-25 03:59AM
Nov-24-25 08:01PM
05:30AM
Nov-21-25 05:27AM
05:10AM
Nov-20-25 04:00AM
Nov-13-25 09:06AM
04:59AM
Nov-12-25 05:55PM
04:40PM
07:20AM
Nov-11-25 07:23AM
Nov-10-25 04:00AM
Nov-07-25 08:10AM
05:20AM
Nov-06-25 09:07AM
08:30AM
Nov-05-25 10:00AM
08:15AM
Nov-04-25 04:01PM
02:00AM
Nov-02-25 05:12PM
Oct-27-25 11:32AM
Oct-22-25 05:00AM
Oct-21-25 03:53AM
Oct-15-25 09:55AM
Oct-09-25 10:19AM
Oct-06-25 08:00AM
04:40AM
Sep-30-25 09:15AM
Sep-24-25 03:42AM
Sep-23-25 12:19PM
Sep-22-25 06:15AM
04:30AM
Sep-19-25 07:45AM
Sep-18-25 09:33AM
Sep-09-25 09:09AM
Sep-04-25 09:15AM
Aug-21-25 04:30AM
Aug-20-25 06:05AM
Aug-14-25 11:41AM
Aug-13-25 05:40PM
04:15PM
09:55AM
Aug-12-25 03:00PM
10:26AM
10:16AM
Aug-06-25 05:15PM
08:00AM
Jul-30-25 10:11AM
Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Robert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.
Founder & Executive ChairmanMr. Vilhelm Robert Wessman
Chief Executive OfficerMs. Lisa Graver
Chief Financial OfficerMs. Linda Jonsdottir
Chief Operating OfficerMr. Joseph E. McClellan
Chief Information OfficerMs. Neha Patel